US health authorities have approved a groundbreaking gene therapy designed to treat a rare inherited form of hearing loss, marking a major milestone in medical science.
The therapy, developed by Regeneron Pharmaceuticals and named Otarmeni, targets a specific genetic condition caused by mutations in the OTOF gene. This gene plays a crucial role in transmitting sound signals from the inner ear to the brain.
The treatment has received accelerated approval from the US Food and Drug Administration and is intended for children and adults suffering from severe-to-profound hearing loss linked to this mutation. The condition affects an estimated 50 newborns annually in the United States.
Administered through a single injection into the ear, the therapy aims to restore natural hearing. In clinical trials involving 20 pediatric patients, around 80 percent showed significant improvement within months.
Experts say the approval represents a major breakthrough, potentially opening doors for similar treatments targeting other genetic causes of hearing impairment.
CCP approves Ranipur Sugar Mills acquisition deal
One of the researchers involved, Eliot Shearer, described the development as the beginning of a new era in treating genetic hearing loss, where continuous natural hearing could become achievable.
Families of patients have also welcomed the innovation. Sierra Smith, whose child underwent the therapy, shared that her son can now respond to sound, enjoy music, and engage with the world in ways that were previously impossible.
Despite gene therapies typically costing millions of dollars, Regeneron has announced plans to provide this treatment free of charge to eligible patients in the US.
Comments are closed, but trackbacks and pingbacks are open.